Phase 3 Readouts — Q2 2027
Phase 3 clinical trial readouts are pivotal moments for biotech companies. These large-scale trials (1,000-5,000+ patients) determine whether a drug has enough evidence of efficacy and safety to seek FDA approval.
86 phase 3 readouts in Q2 2027. Updated .
Phase 3 Topline: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuva
CG Oncology, Inc. (CGON)
Phase 3 Topline: Randomized, Multi-Center, Evaluator-Blind, Vehicle-Controlled Study to Evaluate Efficacy and Safety
Teva Pharmaceutical Industries Limited (TEVA)
Phase 3 Topline: A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
Phase 3 Topline: Effect of a Healthy Food Voucher on Blood Glucose Control in People With Type 2 Diabetes or Prediabe
ENANTA PHARMACEUTICALS INC (ENTA)
Phase 3 Topline: Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Univer
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: An Operationally Seamless, Randomized Phase 2/3 Study Consisting of a Phase 2 Single-Blind, Dose-Eva
Ultragenyx Pharmaceutical Inc. (RARE)
Phase 3 Topline: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficac
Vanda Pharmaceuticals Inc. (VNDA)
Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ba
Celldex Therapeutics, Inc. (CLDX)
Phase 3 Topline: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplat
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasita
Incyte Corp. (INCY)
Phase 3 Topline: An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphona
Ultragenyx Pharmaceutical Inc. (RARE)
Phase 3 Topline: US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol
Vistagen Therapeutics, Inc. (VTGN)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of Suzetrig
VERTEX PHARMACEUTICALS INC / MA (VRTX)
Phase 3 Topline: A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Iv
VERTEX PHARMACEUTICALS INC / MA (VRTX)
Phase 3 Topline: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib and Are Judg
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osime
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Effica
Novartis AG (NVS)
Phase 3 Topline: A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Phase 3 Topline: An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futiba
CG Oncology, Inc. (CGON)
Phase 3 Topline: Efficacy of Post-Surgical Stereotactic Radiosurgery for Metastatic Brain Disease: A Randomized Trial
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Follow
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evalua
Viatris Inc (VTRS)
Phase 3 Topline: A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adul
Praxis Precision Medicines, Inc. (PRAX)
Phase 3 Topline: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficac
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluat
AbbVie Inc. (ABBV)
Phase 3 Topline: Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Ad
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a
Definium Therapeutics Inc. (DFTX)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib i
Incyte Corp. (INCY)
Phase 3 Topline: Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and
Sanofi (SNY)
Phase 3 Topline: An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing
CYBIN INC. (HELP)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label, Study to Evaluate REGN7508, A Factor XI Monoclonal A
REGENERON PHARMACEUTICALS, INC. (REGN)
Phase 3 Topline: A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979
REGENERON PHARMACEUTICALS, INC. (REGN)
Phase 3 Topline: A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durv
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Re
Novartis AG (NVS)
Phase 3 Topline: A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Inve
Sanofi (SNY)
Phase 3 Topline: A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evalua
ORAMED PHARMACEUTICALS INC. (ORMP)
Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety o
Novartis AG (NVS)
Phase 3 Topline: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subje
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and
CG Oncology, Inc. (CGON)
Phase 3 Topline: A Phase III Randomised, Double-Blind, Parallel-Group Study to Assess the Effect of Fixed Dose Combin
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Neb
Savara Inc (SVRA)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety
VERTEX PHARMACEUTICALS INC / MA (VRTX)
Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Active-Controlled Phase Ⅲ Clinical Trial to Evaluate the Ef
SINOVAC BIOTECH LTD (SVA)
Phase 3 Topline: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monother
ASTRAZENECA PLC (AZN)
Phase 3 Topline: An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in
Denali Therapeutics Inc. (DNLI)
Phase 3 Topline: COVE-2: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and S
Verrica Pharmaceuticals Inc. (VRCA)
Phase 3 Topline: Randomized Phase III Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX
Jazz Pharmaceuticals plc (JAZZ)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and S
Pharvaris N.V. (PHVS)
Phase 3 Topline: A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema
Pharvaris N.V. (PHVS)
Phase 3 Topline: A Multicentre, Open-label Trial in Healthy Volunteers to Assess the Boostability of Three Different
Prime Medicine, Inc. (PRME)
Phase 3 Topline: An Open-label, Multicenter Clinical Study on The Long-term Safety and Efficacy of Multiple Treatment
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Phase 3 Topline: An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safet
Insight Molecular Diagnostics Inc. (IMDX)
Phase 3 Topline: An Open-Label Safety Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients With Familia
IONIS PHARMACEUTICALS INC (IONS)
Phase 3 Topline: A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy an
BIOGEN INC. (BIIB)
Phase 3 Topline: A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab
ASTRAZENECA PLC (AZN)
Phase 3 Topline: Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a G
Oscar Health Inc. (OSCR)
Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, T
Xenon Pharmaceuticals Inc. (XENE)
Phase 3 Topline: Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Dep
Neumora Therapeutics, Inc. (NMRA)
Phase 3 Topline: A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in S
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of
Alkermes plc. (ALKS)
Phase 3 Topline: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemothe
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and
ARDELYX, INC. (ARDX)
Phase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy,
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects
VERTEX PHARMACEUTICALS INC / MA (VRTX)
Phase 3 Topline: A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified
VERTEX PHARMACEUTICALS INC / MA (VRTX)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Co
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of
REGENERON PHARMACEUTICALS, INC. (REGN)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy
Merck & Co., Inc. (MRK)
Phase 3 Topline: A Multicentre, Randomised, Open-Label, Parallel-Group, Phase IIIb Study to Assess the Potential for
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety o
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma
CG Oncology, Inc. (CGON)
Phase 3 Topline: An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabre
Novartis AG (NVS)
Phase 3 Topline: A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy a
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety
AMGEN INC (AMGN)
Phase 3 Topline: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN ME
PFIZER INC (PFE)
Phase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the
TC BioPharm (Holdings) plc (TCBWF)
Phase 3 Topline: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy an
NYMOX PHARMACEUTICAL CORP (NYMXF)
Phase 3 Topline: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cispla
CG Oncology, Inc. (CGON)
Phase 3 Topline: A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in C
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study t
Galmed Pharmaceuticals Ltd. (GLMD)
Phase 3 Topline: A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SA
Sanofi (SNY)
Phase 3 Topline: Lot-to-lot Consistency and Safety of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried in Healt
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity
Novo Nordisk A/S (NVO)